There are currently 1985 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276
Recruiting
This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery
NCT06349590
Recruiting
A single arm, prospective, single center Phase1/2 Dietary intervention trial for subjects diagnosed with colorectal cancer and scheduled for tumor resection more than 21 days from informed consent. Subjects will be provided 21 days of standardized High-fiber/low-fat meals and complete a food diary up until lunch on the day prior to surgery. Blood samples will be collected at baseline and on the day of surgery. Stool samples will be collected throughout the dietary intervention period at specific... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Colorectal Cancer
Register for Updates
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05005728
Recruiting
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: The University of Chicago Medical Center, Chicago, Illinois
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
Auricular Acupressure in Prehabilitation
NCT06516198
Recruiting
Complementary medicine is recognized for its ability to enhance appetite, increase energy, reduce anxiety, decrease pain, and improve sleep, among many other benefits. Acupuncture is among the most frequent types of complementary medicine practiced in the US, and Medicare currently includes back pain as a reimbursable indication for this therapy. Acupuncture-related therapies may enhance efforts at prehabilitation in candidates for major lung resection.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/08/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Frailty, Thoracic, Prehabilitation, Lung Surgery, Wedge Resection, Segmentectomy, Lobectomy, Pneumonectomy; Status
Register for Updates
Empowering Veterans to Actively Communicate and Engage in Shared Decision Making in Medical Visits, A Randomized Controlled Trial
NCT05169359
Recruiting
Type 2 diabetes is a significant condition in VA affecting 20% of VA patients. Adherence to medication regimens and lifestyle factors is important to achieve care goals for these patients. Patients who use active participatory communication behaviors with their providers have better adherence to treatment and better biomedical outcomes, yet many patients are not prepared to engage in active communication with their providers. Existing coaching interventions have not been adopted in practice beca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Lakeside VA Clinic, Chicago, Illinois +1 locations
Conditions: Diabetes Mellitus (Type 2)
Register for Updates
CIED Infection Quality Initiative Demonstration Project
NCT05471973
Recruiting
The aim of this Quality Initiative (QI) demonstration project is to develop a model to increase guideline-driven care for patients with cardiovascular implantable electronic devices (CIED) infection. Multidisciplinary teams will be established to carry out the multifaceted intervention. This program seeks to improve early identification and diagnosis, appropriate treatment, and faster time to treatment of CIED infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Northwestern, Chicago, Illinois
Conditions: Infections
Register for Updates
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
NCT06499870
Recruiting
This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy. It prevents the release of testosterone, a hormone required to sustain prostate growth. Reducing testosterone levels may inhibit the proliferation of prostate tumor cells that need testosterone to grow. Enzalutamide is an androgen receptor signaling inhibitor. It inhibits the acti... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Prostate Adenocarcinoma
Register for Updates
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: the SOLAR Trial
NCT04883671
Recruiting
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: * Stereotactic Body Radiation Therapy (SBRT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Register for Updates
GU-01: Glycyrrhizin in Prostate Cancer
NCT06378346
Recruiting
This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of Illinois, Chicago, Illinois
Conditions: Prostate Cancer
Register for Updates
Fisetin to Reduce Senescence and Mobility Impairment in PAD
NCT06399809
Recruiting
The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in peop... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/06/2024
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Peripheral Arterial Disease, Aging, Peripheral Vascular Diseases, Walking, Difficulty, Claudication
Register for Updates
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
NCT05755035
Recruiting
The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16 years old and older. The participants will be treated with TAK-881/HYQVIA or HYQVIA/TAK-881 with the same dose and dosing interval of immunoglobulin for up to 51 weeks (for participants greater than or equal to \[\>=\]16 years) and only with TAK-881 for up to 27 weeks (... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
10/04/2024
Locations: Rush University Medical Center - University Cardiovascular Surgeons, Chicago, Illinois
Conditions: Primary Immunodeficiency Diseases (PID)
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Local Institution - Unk062, Chicago, Illinois +1 locations
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates